BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9193363)

  • 1. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
    Janicek M; Kaplan W; Neuberg D; Canellos GP; Shulman LN; Shipp MA
    J Clin Oncol; 1997 Apr; 15(4):1631-7. PubMed ID: 9193363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
    Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
    J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
    Frohlich DE; Chen JL; Neuberg D; Kehoe KM; Van den Abbeele AD
    J Nucl Med; 2000 Feb; 41(2):269-74. PubMed ID: 10688110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
    Zijlstra JM; Hoekstra OS; Raijmakers PG; Comans EF; van der Hoeven JJ; Teule GJ; Jonkhoff AR; v Tinteren H; Lammertsma AA; Huijgens PC
    Br J Haematol; 2003 Nov; 123(3):454-62. PubMed ID: 14617005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Anderson JR; Harrison KA; Dalrymple GV; Byar K; Kessinger A; Armitage JO
    J Clin Oncol; 1996 Sep; 14(9):2473-9. PubMed ID: 8823325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
    Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
    J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
    Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease.
    King SC; Reiman RJ; Prosnitz LR
    J Clin Oncol; 1994 Feb; 12(2):306-11. PubMed ID: 8113837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
    Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.